Molecular Investigation of Isocitrate Dehydrogenase Gene (IDH) Mutations in Gliomas: First Report of IDH2 Mutations in Indian Patients |
Ranjan Das, Bibhu
(Research and Development, SRL Ltd.)
Tangri, Rajiv (SRL Ltd.) Ahmad, Firoz (Research and Development, SRL Ltd.) Roy, Arnab (Research and Development, SRL Ltd.) Patole, Kamlakar (Histopathology Division, SRL Ltd.) |
1 | Bleeker FE, Lamba S, Leenstra S, et al (2009). IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat, 30, 7-11. DOI ScienceOn |
2 | Burger PC, Scheithauer BW, Paulus W, et al (2000). Pilocytic astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press, 45-51. |
3 | Cykowski MD, Allen RA, Fung KM, et al (2012). Pyrosequencing of IDH1 and IDH2 mutations in brain tumors and nonneoplastic conditions. Diagn Mol Pathol, 21, 214-20. DOI |
4 | Felsberg J, Wolter M, Seul H, et al (2010). Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol, 119, 501-7. DOI |
5 | Hartmann C, Meyer J, Balss J, et al (2009). Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-74. DOI ScienceOn |
6 | Horbinski C, Kofler J, Kelly LM, et al (2009). Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol, 68, 1319-25. DOI |
7 | Jha P, Suri V, Sharma V, et al (2011). IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol, 91, 385-93. DOI ScienceOn |
8 | Jones DT, Kocialkowski S, Liu L, et al (2008). Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res, 68, 8673-7. DOI ScienceOn |
9 | Koivunen P, Lee S, Duncan CG, et al (2012). Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 483, 484-8. DOI ScienceOn |
10 | Krell D, Assoku M, Galloway M, et al (2011). Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One, 6, 19868. DOI |
11 | Losman JA, Looper RE, Koivunen P, et al (2013). (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science, 339, 1621-5. DOI ScienceOn |
12 | Metellus P, Coulibaly B, Colin C, et al (2010). Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol, 120, 719-29. DOI ScienceOn |
13 | Mukasa A, Takayanagi S, Saito K, et al (2012). Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci, 103, 587-92. DOI ScienceOn |
14 | Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. DOI ScienceOn |
15 | Qi ST, Yu L, Lu YT, et al (2011). IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncol Rep, 26, 1479-85. |
16 | Raynaud S, Carbuccia N, Colin C, et al (2010). Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncol Lett, 1, 883-4. DOI |
17 | Uno M, Oba-Shinjo SM, Silva Rd, et al (2011). IDH1 mutations in a Brazilian series of Glioblastoma. Clinics (Sao Paulo), 66, 163-5. DOI ScienceOn |
18 | Sanson M, Marie Y, Paris S, et al (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol, 27, 4150-4. DOI ScienceOn |
19 | Song Tao Q, Lei Y, Si G, et al (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci, 103, 269-73. DOI ScienceOn |
20 | Turcan S, Rohle D, Goenka A, et al (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483, 479-83. DOI ScienceOn |
21 | Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res, 16, 1597-604. DOI |
22 | WickW, Hartmann C, Engel C, et al (2009). M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol, 27, 5874-80. DOI ScienceOn |
23 | Yan H, Parsons DW, Jin G, et al (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360, 765-73. DOI ScienceOn |
24 | Zhu J, Zuo J, Xu Q, et al (2011). Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses, 76, 602-3 DOI ScienceOn |
![]() |